#US Acute Myeloid Leukemia Market demand

[sarkos]

For the past decade, the Dutch immunologist Jacques (Sjaak) Neefjes has been on a mission to bring back a cancer drug that hasn’t been available in Europe since 2004. “I’m still flabbergasted that a compound that could have helped thousands of people was taken off the market,” says Neefjes. Why it was removed seems something of a mystery, but as far as he can tell, it was simply a lack of demand. His latest research shows that this drug, aclarubicin, can improve the survival of people with acute myeloid leukemia (AML) much better than other forms of chemotherapy. If it had been available in Europe for the past 20 years, Neefjes estimates that it could have helped 100,000 people. But while the maths sounds simple, the path of Neefjes’s research has been far from smooth. In his attempts to revive aclarubicin, he has smuggled small amounts from China, found old samples in a Finnish freezer, and funded part of his work using an inheritance from a Dutch MP who was murdered 10 years ago. “It has been a tough battle,” says Neefjes. And it’s nowhere near over. Next, he has to produce enough of the drug to run clinical trials for AML patients in Europe.

One man’s mission to revive a forgotten, life-saving cancer drug | Cancer research | The Guardian

[priteshwemarketresearch]

Olutasidenib Market Research Trends Analysis by 2024-2034

Olutasidenib Market Introduction:

Olutasidenib is emerging as a pivotal drug in the oncology field, targeting cancers with specific genetic mutations. Developed to inhibit the mutant form of the isocitrate dehydrogenase 1 (IDH1) enzyme, olutasidenib offers a targeted approach for treating cancers driven by IDH1 mutations, particularly acute myeloid leukemia (AML).

Unlock your exclusive sample PDF now:

Market Trends

Increasing Adoption in Clinical Practice: Olutasidenib's clinical trials have shown promising results, particularly in treating acute myeloid leukemia (AML) and other hematologic malignancies. The drug's effectiveness in targeting IDH1 mutations has garnered interest from oncologists, leading to its gradual adoption in clinical settings. As more data becomes available, the use of olutasidenib is expected to become more widespread, further driving market growth.

Growing Pipeline of IDH1-Mutant Cancers: The olutasidenib market is benefiting from an expanding pipeline of IDH1-mutant cancers. Research is ongoing to evaluate the drug's efficacy in various cancer types beyond AML, including solid tumors. This broadening scope is likely to enhance market potential and create new opportunities for pharmaceutical companies.

Increasing Investment and Partnerships: Pharmaceutical companies are investing heavily in the development and commercialization of targeted therapies like olutasidenib. Strategic partnerships and collaborations are becoming more common as companies seek to leverage each other’s strengths in research, development, and market access. These alliances are crucial for accelerating the drug’s availability and expanding its reach.

Opportunities in the Olutasidenib Market

Expanding Indications: While olutasidenib is currently approved for specific indications, there is significant potential for expanding its use. Ongoing research is exploring its effectiveness in additional cancer types and stages. Successfully gaining approval for these new indications could substantially increase the drug's market share.

Global Market Expansion: As the drug continues to demonstrate its efficacy, there is a growing opportunity for global market expansion. Different regions may have varying rates of IDH1-mutant cancers, which could influence the drug's market dynamics. Companies that successfully navigate regulatory pathways in diverse markets will have a competitive advantage.

Personalized Medicine: The rise of personalized medicine is a key factor driving the olutasidenib market. With a focus on precision oncology, treatments are increasingly tailored to the genetic profiles of individual patients. Olutasidenib’s targeted approach aligns well with this trend, offering the potential for more effective and personalized cancer treatment.

Olutasidenib Market  Segments

by Type

Generic Olutasidenib

Branded Olutasidenib

       by Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Olutasidenib Market  Key Market Players

AbbVie Inc.

Olutasidenib Industry: Regional Analysis

North America Market Forecast

With a Olutasidenib Market share of more than 47%, North America leads the global olutasidenib industry in terms of revenue generation. Because of its sophisticated healthcare system and large R&D expenditures, North America is one of the top markets for olutasidenib. Novel treatments are highly sought for due to the high incidence of acute myeloid leukemia (AML) and the large number of clinical studies carried out in the United States and Canada. Market potential is further enhanced by this region's established healthcare infrastructure and emphasis on innovative treatments.

European Market Data

Europe's market for olutasidenib is bolstered by its extensive clinical research endeavors and strong healthcare infrastructure. Demand is increased by the high cancer incidence rates and favorable regulatory regimes found in nations like Germany, France, and the UK. The potential for Olutasidenib's expansion in Europe is enhanced by the region's investment in cancer research and development, as well as the enhancement of patient access to innovative medicines.

Challenges and Considerations

High Development Costs: Developing and bringing a novel drug to market involves substantial investment. The costs associated with clinical trials, regulatory approvals, and market access can be significant. Companies must carefully manage these expenses to ensure a favorable return on investment.

Competition and Market Saturation: The oncology market is highly competitive, with numerous therapies targeting similar pathways. As more drugs enter the market, olutasidenib will need to demonstrate clear advantages in efficacy and safety to maintain its competitive edge.

Regulatory Hurdles: Navigating the regulatory landscape can be complex and time-consuming. Companies must adhere to rigorous standards to gain approval for new indications and international markets. Successfully overcoming these regulatory hurdles is essential for maximizing market potential.

Olutasidenib and Clinical Trials

Before its approval, Olutasidenib Market  underwent rigorous clinical trials to evaluate its safety and efficacy. These studies demonstrated promising results in terms of:

Response Rate: A significant number of patients experienced complete or partial remission of their AML.

Survival: Patients treated with olutasidenib showed improved overall survival compared to standard treatment options.

Key benefits of olutasidenib include:

Targeted therapy: Specifically addresses the underlying genetic cause of AML in patients with the IDH1 mutation.

Oral administration: Convenient and patient-friendly compared to traditional intravenous chemotherapy.

Improved outcomes: Demonstrated effectiveness in clinical trials, leading to increased response rates and improved survival.

Future Outlook

The future of the olutasidenib market appears promising, with ongoing research and development efforts poised to enhance its therapeutic potential. As the drug continues to show efficacy in clinical trials and expands its indications, it is likely to become a cornerstone of treatment for IDH1-mutant cancers. Additionally, advancements in personalized medicine and global market expansion will further drive growth.

Conclusion,

Olutasidenib represents a significant advancement in targeted cancer therapy. Its market trajectory will be shaped by continued research, strategic partnerships, and the evolving landscape of oncology. For investors, healthcare professionals, and patients alike, the Olutasidenib Market  offers a glimpse into the future of personalized and effective cancer treatment.

[wellnessweb]

Leukemia Therapeutics Market Size: Competitive Landscape Analysis

The Leukemia Therapeutics Market size was USD 16 Billion in 2023 and is expected to Reach USD 27.28 Billion by 2031 and grow at a CAGR of 6.9% over the forecast period of 2024-2031.The leukemia therapeutics market is experiencing rapid growth, driven by advancements in targeted therapies and personalized medicine. With an increasing understanding of the genetic and molecular mechanisms underlying various leukemia subtypes, pharmaceutical companies are developing innovative treatments that offer improved efficacy and reduced side effects. The market is also benefiting from a surge in research and development activities, coupled with supportive regulatory frameworks that expedite the approval process for novel drugs. Furthermore, the rise in leukemia prevalence, along with heightened awareness and early diagnosis, is expanding the patient pool eligible for these cutting-edge therapies. This dynamic landscape presents significant opportunities for stakeholders, ranging from biotech startups to established pharmaceutical giants, to make impactful contributions to leukemia care and patient outcomes.

Get Sample of This Report @ https://www.snsinsider.com/sample-request/3135

Market Scope & Overview

The market report gives thorough information to help readers comprehend the current situation of the industry. The report relied on primary and secondary research, as well as private databases and a paid data source. The market research report sheds light on the history and future of the Leukemia Therapeutics Market business. The report analyses the market size and includes information on market drivers, limitations, and opportunities.

The market research report examines the primary strategies used by top industry players to advance their operations in the worldwide market while maintaining a competitive advantage over their competitors. The Leukemia Therapeutics Market  study also depicts the competitive landscape of the industry's major competitors, as well as the top organizations’ percentage market share.

Market Segmentation Analysis

By Type

Chronic Lymphocytic Leukemia

Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia

Acute Myeloid Leukemia

Others

By Drug Class

Targeted Therapy

Chemotherapy and Immunotherapy

By Distribution channel

Hospital Pharmacies

Online Providers

Drug Store

Retail Pharmacies

COVID-19 Pandemic Impact Analysis

In this Leukemia Therapeutics Market  analysis, the impact of COVID-19 on the market is analyzed at both the global and country levels. According to this analysis, the COVID-19 pandemic and the post-pandemic phase had a significant impact on both the supply and demand sides of the market.

Regional Outlook

The report's accurate data will help market participants make informed decisions about regional expansions and investments. The report looks at the dynamics of the Leukemia Therapeutics Market  in relation to worldwide market conditions.

Competitive Analysis

The data in this section will assist readers in understanding the primary strategies used by leading market players to control the global Leukemia Therapeutics Market . The research report includes a PORTER, SVOR, and PESTEL analysis, as well as an examination of the potential impact of microeconomic market variables. External and internal elements that are projected to have an impact on the company have been studied, presenting decision-makers with a clear picture of the industry's future.

Key Questions Answered in the Leukemia Therapeutics Market  Report

What is the forecasted growth rate, market share, and m market size?

Who are the market's dominant players, and how have they gained a competitive advantage over their competitors?

Conclusion

The Leukemia Therapeutics Market  research report's estimations and estimates examine the impact of different political, social, and economic factors, as well as current market conditions, on market growth. All of this important information will assist the reader in better understanding the market.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Protein Engineering Market Share

AI in Cancer Diagnosis Market Share

Blood Group Typing Market Share

Immunomodulators Market Share

Lymphoma Treatment Market Share

[pharmanucleus1]

Global Leukemia Therapeutics Market, Forecast 2027

Leukemia Therapeutics Market

Leukemia is a type of blood cancer caused by gene mutation leading to abnormal development of WBCs in the bone marrow and causes leukemia. Leukemia is also caused due to risk factors such as genetic disorders such as Down syndrome, previous cancer treatments, exposure to chemicals, smoking, and family history of leukemia or other blood disorders. The major types of leukemia are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL). The majority of the AML, CML & CLL cases could be observed in adult populations, and ALL could be seen in all age groups. Leukemia treatment is based on its type, age, and ability to cope-up with the treatments. 

Market Size & Growth Rate: 

The leukemia therapeutics market was valued at USD 13.5 billion in 2021 and is projected to reach USD 17.1 billion by 2027, with a CAGR of 7.2% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies. 

Click here for full report:

https://www.pharmanucleus.com/reports/leukemia-therapeutics-market

Market Dynamics: 

On account of the growing number of people suffering from leukemia, the leukemia therapeutics treatment market has been driven by technological research & developments, the merging of healthcare organizations and new approvals in the field of blood cancer diagnostics across the globe. 

The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP)-April 2021, announced five new investments in increasing the development of new and improved immunotherapies in Abintus Bio, Nexlmmune, Caribou Biosciences and Immune-Onc Therapeutics for the treatment of leukemia cancer. 

Moreover, raising public awareness about the benefits of preventive healthcare is likely to move the demand for leukemia therapeutics treatment forward throughout the forecast period. Additionally, the Government initiatives and programs at increasing cancer awareness are expected to drive leukemia therapeutics treatment market expansion until 2027. 

Market Drivers: 

The growing research and technological development activities. 

Increasing product approval and product launch by the market players are expected to propel the leukemia therapeutics market, and also technological developments are likely to create various new opportunities that will impact this leukemia therapeutics market growth in the forecast period. For instance, 

In May 2022, Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) received FDA approval for combination with azacitidine in newly diagnosed AML with a susceptible IDH1 mutation in adults 75 years and older. 

On June 2021, Jazz Pharmaceuticals received FDA approval for a new form of Rylaze (asparaginase erwinia chrysanthemi recombinant rywn) to be developed as part of a treatment for children and adults with ALL 

In October 2021, Kite Pharma received FDA approval for use of the CAR T-cell therapy brexucabtagene autoleucel developed by Tecartus (the first CAR T-cell therapy approved) in adults with B-cell precursor ALL 

In November 2018, Pfizer Inc. received U.S. FDA approval for Glasdegib (DAURISMO), the Hedgehog pathway inhibitor for the treatment of adults suffering from AML 

Increasing incidence of leukemia to boost leukemia therapeutics market growth. 

One of the foremost driving factors influencing the global market is the increasing prevalence of leukemia across the globe, according to the National Cancer Institute (NCI), approximately 1.5% of people were diagnosed with leukemia during their lifetime. Additionally, in the report-2022, the estimated number of living people with new leukemia cases will be 60,650, and the number of death cases will be 24,000 in the United States. 

According to the American Cancer Society-2022, the CLL segment is anticipated 20,160 diagnosis cases including both children & adults in US leukemia therapeutic market, as CLL is the first line of treatment for it followed by AML and CML. 

Click here for full report:

Get more details on this report - Request Free Sample

Substantial progress has been made against cancer in recent decades. As of 2019, the rate has declined by 32%, mostly because of advances in early detection and treatment for some cancers including leukemia. It reflects largely driven by progress against leukemia cancer. 

Challenges: 

The high cost of treatment and stringent regulatory scenario restrain the market growth. 

High cost of treatment and stringent regulatory scenario restraint the market growth over the forecast period. For instance, the NCI-2022 report estimates that cancer-related direct medical costs in the US were USD 183 billion in 2015 and are projected to increase to USD 246 billion by 2030, a 34% increase based only on population growth and aging. 

The low diagnosis rate of leukemia & lack of proper healthcare facilities in developing countries 

Adverse reactions of leukemia therapeutics 

Competitive landscape:                                                                                                                     

Novartis International AG, Bristol Myers Squibb, Sanofi S.A, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical, Celgene Corporation, GlaxoSmithKline plc, Abintus Bio, Nexlmmune, Exelixis Inc., MorphoSys AG, Otsuka Holdings Company Ltd, AbbVie, Ambit Biosciences corporation, Ariad Pharmaceuticals, Gennzme Corporation, Rpche,  and Others. 

Key Developments: 

Get more details on this report - Request Free Sample

Regional Analysis: 

North America was the largest region in the leukemia therapeutics market in recent years and it is anticipated to capture the highest share of this market over the forecast period 2022-2027, with the U.S. accounting for the maximum contribution and it has well-developed structural healthcare systems. In addition, the high prevalence of leukemia and the rising geriatric population, based on the NCI-2022 report, leukemia represents 3.2% of all new cancer cases in the U.S., and the incidence rate increased in children and adolescents by about 1% per year and was stable in adults ages 20 and older. The presence significant of key players, some of the best research universities, and encouraging new product developments & launches for research lead to more significant assets in the pipeline. For instance, 

In October 2022, The American Cancer Society (ACS) approved funding for 89 new Extramural Discovery Science (EDS) research grants totaling USD 54.3 million. It will fund investigators at 65 institutions across the United States from January 1, 2023.?                                                                                                       

In November 2021, Pfizer Company acquired Trillium Therapeutics for approximately USD 2.22 billion, to enhance its oncology portfolio with the addition of next-generation immune therapies. 

[meghanester]

Hematopoietic Stem Cells Transplantation Market 2023-2035 to Grow at a CAGR of ~15% Driving Factors, Size, Revenue, Segments, Expansion, Demand

Global Hematopoietic Stem Cells Transplantation Market Key Insights

During the forecast period of 2023-2035, the global hematopoietic stem cells transplantation market is expected to reach an estimated value of ~USD 6,000 billion by 2035, by expanding at a CAGR of ~15%. The market further generated a revenue of ~USD 2,500 million in the year 2022. Major key factors propelling the growth of hematopoietic stem cells transplantation market worldwide are the increasing prevalence of cancer and the rising prevalence of hematopoietic stem cell transplantation.

Market Definition of Hematopoietic Stem Cells Transplantation

Hematopoietic stem cell transplantation is a process of sourcing healthy multipotent stem cells for replacing the old degenerative cells of the body. After the transplantation of healthy hematopoietic stem cells in the patient’s body, they produce red blood cells, white blood cells, and platelets to repair and replace the patient’s hematopoietic system. The procedure is done to cure a disease, such as cancer, or bone marrow failure, and even in some cases to change the gene pattern. These cells are sourced from the umbilical cord of a baby, peripheral blood cells, and matching bone marrow.

Request Free Sample Copy of this Report @ https://www.researchnester.com/sample-request-3937

Global Hematopoietic Stem Cells Transplantation Market: Growth Drivers

The growth of the global hematopoietic stem cells transplantation market can majorly be attributed to the higher number of people suffering from cancer and the deaths attributed to cancer, followed by the growing adoption of hematopoietic stem cells transplantation. According to the World Health Organization, in 2020, around 10 million deaths were caused by cancer and it was known as the leading cause of death in the world. Moreover, every year, around 400,000 children develop cancer in the world. Furthermore, as of 2020, in the world, around 2 million hematopoietic cell transplants have been carried out in the world and there are around 1,500 transplantation centers are set up in the world. On the other hand, the market growth can also be attributed to the rising need for kidney transplantation. In order to stay alive, around 2 million people in the world need dialysis and kidney transplantation.

The global hematopoietic stem cells transplantation market is also estimated to grow majorly on account of the following:

Rising Cases of Cancer

Number of People Suffering from Organ Failure

Rise in Research and Development on Stem Cells

Increasing Number of Hematopoietic Stem Cells Transplant

Development of Customized Drugs

Request for customization @ https://www.researchnester.com/customized-reports-3937

Global Hematopoietic Stem Cells Transplantation Market: Restraining Factor

Hematopoietic stem cells transplantation is also known to be associated with side effects to the heart, lungs, mouth, and others. Besides this, the cost of the treatment is very high and, in many places, there is a shortage of skilled experts who can perform the transplantation. Hence, these factors are expected to be the major hindrance to the growth of the global hematopoietic stem cells transplantation market during the forecast period.

Global Hematopoietic Stem Cells Transplantation Market Segmentation 

By Transplant Type (Allogenic, and Autologous)

By Disease Type (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Multiple Myeloma, and Others)

The multiple myeloma segment, amongst all the other segments, is anticipated to garner the largest revenue by the end of 2035. The growth of the segment can be attributed to the growing cases of multiple myeloma in the world and the surge in use of stem cell transplantation to treat multiple myeloma. In 2020, there were 131,518 cases of multiple myeloma for every 100,000 people, according to the IARC database. Furthermore, in the United States, around 34,000 adults are suffering from multiple myeloma. Moreover, nearly 13,000 people die of the disease in the nation, and approximately 120,000 deaths were reported worldwide in 2020.

By Application (Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), Cord Blood Transplant (CBT), and Others)

By Region

The North America hematopoietic stem cells transplantation market is anticipated to hold the largest market share by the end of 2035 among the market in all the other regions. The market size of North America is expected to grow on the account of rising cases of cancer and a higher number of transplants carried out in the region.   The number of organ transplants carried out in the United States increased to 41,354 in 2021. It is approximately 6% higher than the previous higher. Furthermore, in 2022, around 61,000 new cases of leukemia were reported in the United States, and nearly 24,000 deaths were attributed to it.

Know More About the Complete Study @ https://www.researchnester.com/reports/hematopoietic-stem-cells-transplantation-market/3937

The market research report on global hematopoietic stem cells transplantation also includes the market size, market revenue, Y-o-Y growth, and key player analysis applicable for the market in North America (U.S., and Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), and Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa).

Key Market Players Featured in the Global Hematopoietic Stem Cells Transplantation Market

Some of the key players of the global hematopoietic stem cells transplantation market are Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., Lonza Group Ltd., CSG-BIO Company, Inc., CBR Systems, Inc., Pluristem Inc., Global Cord Blood Corporation, ViaCord, LLC, Cynata Therapeutics Limited, and others.

About Research Nester

Research Nester, which is a leading service provider for strategic market research and consulting services, aims to provide unbiased, unparalleled market insights and industry analysis. These analyses help conglomerates, executives, and industries to take wise decisions for their businesses as well as for their future marketing strategy, expansion and investment among others. We believe that our expertise in the field of market research can help businesses to expand to its new horizon. Our team of research analysts can provide businesses a right guidance at the right time, while our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

[cmipooja]

Global Dasatinib Drugs Market Is Estimated To Witness High Growth Owing To Increasing Demand for Targeted Cancer Therapies

The global Dasatinib Drugs Market is estimated to be valued at US$ 4.35 billion in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights. Market Overview: Dasatinib is an oral medication used for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is classified as a tyrosine kinase inhibitor and works by blocking the action of abnormal proteins that signal the growth of cancer cells. The advantages of dasatinib include its high efficacy in treating CML, ability to target specific cancer cells, and reduced side effects compared to traditional chemotherapy. The increasing incidence of CML and the demand for targeted cancer therapies are driving the growth of the dasatinib drugs market. Market Key Trends: One key trend in the dasatinib drugs market is the growing focus on precision medicine. Precision medicine aims to tailor treatment strategies based on a patient's genetic makeup, lifestyle, and environmental factors. Dasatinib, being a targeted therapy, aligns with the principles of precision medicine by selectively inhibiting specific cancer cells, thereby reducing the likelihood of adverse effects. For example, research studies have identified specific mutations in the BCR-ABL gene, which can affect the response to dasatinib treatment. This trend emphasizes the importance of personalized therapies and molecular testing in optimizing patient outcomes. PEST Analysis: - Political: Government regulations and policies related to drug approvals, intellectual property rights, and reimbursement can significantly impact the availability and affordability of dasatinib drugs. - Economic: The cost-effectiveness of dasatinib drugs compared to other treatment options, as well as healthcare expenditure and insurance coverage, can influence market growth. - Social: The increasing prevalence of cancer, especially CML, and the awareness and acceptance of targeted therapies among patients and healthcare professionals are driving market demand. - Technological: Advances in genetic testing technologies and biomarker identification are enabling the identification of patients who are likely to benefit the most from dasatinib treatment. Key Takeaways: 1: The Global Dasatinib Drugs Market Demand is expected to witness high growth, exhibiting a CAGR of 6.0% over the forecast period, due to increasing demand for targeted cancer therapies. Dasatinib's efficacy in treating CML and its ability to selectively target specific cancer cells position it as a preferred treatment option. 2: In terms of regional analysis, North America is expected to dominate the dasatinib drugs market due to the high prevalence of CML in the region and the well-established healthcare infrastructure. Asia Pacific is projected to be the fastest-growing region, driven by the increasing incidence of CML and the rising adoption of targeted therapies. 3: Key players operating in the global dasatinib drugs market include Bristol-Myers Squibb Company, Novartis International AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Ltd., Hetero Drugs Limited, Natco Pharma Limited, Dr. Reddy's Laboratories Ltd., and Aurobindo Pharma Ltd. These companies focus on research and development activities to develop innovative therapies and expand their product portfolios.

[healthcareandwellness-blog]

Hypomethylating Agents Market: Introduction

Hypomethylating agents act as an essential tool in the treatment of health disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia. These are not the only available treatment options, but their use can further be integrated and optimized in a sequential treatment strategy. The hypomethylating agents are also called as DNA methyltransferase inhibitors. These have allowed the treatment of frail and higher-risk elderly patients.

Request for a sample copy of this report @ https://www.insightsandreports.com/request-sample/188

Market Dynamics

Increasing MDS cases among the population within the age group of above 50 years is one of the major reasons driving the hypomethylating agents’ market significantly. According to the American Cancer Society, the number of people who are diagnosed with MDS in the U.S. every year is unknown, but according to a study conducted by this society, around 10,000 cases are being registered in the U.S. alone, while some other estimates are much higher.

This health disorder is highly uncommon before the age of 50, and moreover, the health risks associated with disease gradually increases along with the person’s age. In the U.S., the new cases diagnosed each year are rising, as the average person’s age among the U.S. population is increasing. As the chances of disease outbreak are higher for this age group, the demand for hypomethylating agents is also predicted to grow over the forecast period.

Moreover, growing allogeneic stem cell transplants along with higher intensity approaches for the treatment of MDS, is expected to yield higher response rates and can also control the disease’s negative impact for longer times. These type of treatment facilities are increasing across the world, which will give an additional boost to the growth of hypomethylating agents market.

Hypomethylating agents market is expected to restrain, owing to the unmet need for sound treatment options among the patients. Moreover, the response rates of these agents for the control of disease’s impact is also very low, according to the National Institute of Health and American Cancer Society. These factors are expected to restrain the hypomethylating agents market significantly over the forecast period.

By Type of Treatment

By type of treatment, the hypomethylating agents market has been segmented into acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). Hypomethylating agents market for myelodysplastic syndromes is expected to have the dominant market share over the forecast period. Increasing new cases, coupled with the developing treatment options for this disorder are expected to attribute the prime share of hypomethylating agents market for myelodysplastic syndromes.

By Gender

Based on gender, the global hypomethylating agents market has been segmented into male and female. Over the forecast period, the use of hypomethylating agents for male population is projected to dominate the product use among female population. This is majorly due to the higher disease incidence chances among men, compared to women. According to the estimates by the American Cancer Society, in 2017, around 19,520 new cases of AML have been identified in the U.S. alone, out of which more than 10,670 deaths are observed, which are mostly among adults, especially among men.

By Region

North America hypomethylating agents market is expected to have the prime share in the global market over the projected period. It is majorly attributed by the increasing cases, and growing treatment facilities, along with the presence of major research organizations (NIH, ACS), and pharmaceutical companies, which are currently striving towards the research and development of new drugs to treat MDS, and AML.

Asia Pacific hypomethylating agents market is expected to witness a higher growth over the forecast period, majorly owing to the presence of key pharmaceutical companies. Manufacturing companies in this region are majorly focusing on the development of these agents, owing to the increasing cases of MDS and AML. Moreover, the governing bodies of several countries in this region are majorly focusing on the development of healthcare industry, which will provide lucrative opportunities for the hypomethylating agents market to grow over the forecast period.

Competitive Landscape

Some of the prominent players in the global hypomethylating agents market include Pfizer, Blue Point Laboratories, Actavis Pharma Company, Dr. Reddy’s Laboratories, Celgene, Cipla Limited, Otsuka Pharmaceuticals, Astex Pharmaceuticals, etc. among others.

Some key pharmaceutical companies such as Cipla Limited and Otsuka Pharmaceuticals are working constantly to get FDA approvals of the drugs developed. For instance, Cipla Limited received a final approval from the U.S. FDA for its generic drug Dacogen in November 2017.

Also, many prominent players are trying to obtain the rights from generic drug manufacturers to expand their geographic horizon in the global hypomethylating agents market. For instance, in March 2014, Otsuka Pharmaceuticals acquired rights from EISAI Inc. for the development and marketing of Dacogen in U.S., Canada, and Japan markets. 

For more information about this report @ https://www.insightsandreports.com/industry-reports/hypomethylating-agents-market

About Us:

Insights and Reports is a research and consulting group assisting the clients with 360-degree insights with real time qualitative and quantitative information. The Insights and Reports team is valued for continuous client-oriented services. Our data scientists monitor the markets pertaining to their expertise on a daily basis with the help of 150+ analysts to back them with accurate market studies.

 Contact Us:

Mr. Saby

Insights And Reports

2201 Cooperative Way #600,

Herndon, VA 20171, USA.

Tel: +1 703 574 4447

Email: sales@insightsandreports.com

[udaycmi]

Blood Cancer Drugs Market to Generate Exciting Opportunities in the Industry by 2027

The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.

The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

Request For Discount: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[techsciresearch]

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

According to TechSci Research report, “Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026”, The Saudi Arabia Poultry market is expected to witness steady growth in the forecast period. The rapid urbanization of the people to live in better conditions and search for employment opportunities is contributing to the growth of the poultry market and enhancing the demand for processed and unprocessed chicken and eggs.

Support of the leading authorities for the development of the poultry market in form of relaxation in income tax, direct subsidies for select food items, interest-free loans, and duty-free imports of raw materials. The leading authorities are providing support to the local manufacturers and taking significant measures to reduce the mortality rate of the bird. An increase in the preference of the consumers for low-fat and high-protein-containing food items is fostering the growing demand of the market. The development of the trade channel and the technological advancements to keep the freshness of the food items and aid in increasing the shelf life of the edible animal food items is fostering the growth of the poultry market.

The increase in the demand for frozen and chilled food items is influencing the demand for poultry-based products in the region. The high demand for the consumption of poultry-based products and the unavailability of quality animal-based edible items in the country and the need to import the animal-based food items are creating lucrative opportunities for the growth of the poultry market. The Saudi government is making heavy investments for the infrastructural development of the country in order to develop the retail and hospitality sector in the country. Under the Saudi Vision 2030, the development of the tourism industry to attract more tourists to the country for religious and other purposes, the government is aiming to develop the poultry sector to meet the growing food requirements.

The COVID-19 outbreak across the world which has been declared as a pandemic by World Health Organization has affected several countries adversely. Leading authorities of Saudi Arabia imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. The coronavirus pandemic hit the economic status of the country which negatively impacted the growth of the industry. Disruption in the supply chain was observed which adversely affected the supply of raw materials around the country.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Saudi Arabia Poultry market is segmented into type, product type, nature, distribution channel, regional distribution, and company. Based on the type, the market can be divided into broiler, eggs, and others. The broiler segment is expected to witness growth in the next five years, 2022-2026. The rise in the demand for whole chicken and its parts and the increasing affordability of the consumers is fostering the growth of this segment. The Hajj pilgrimage attracts a lot of tourists in the country which is expected to fuel the demand and rapid development of the catering service market.  The rise in the development of the construction industry and the liability of the company to provide three meals a day is contributing to the growth of the poultry market as the normal diet in Saudi Arabia includes the portion of animal meat or products.

Almarai Saudi Arabia, Al-Watania Poultry Company, Al-Fakeih Poultry, Al-Berri United Food Co. Ltd, Alwadi Poultry Farms Ltd, Co., Arabian Agricultural Services Company, Arabian Farms Dev.Co.Ltd., Alsalamah Almotatawera Co, BRF S.A, Bayle S.A., Cargill Incorporated, Cherkizovo Group are the leading players operating in Saudi Arabia Poultry market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several Poultry manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

“Development of the online commerce channels to improve the reach of products and brand image, the market players are investing huge amounts. The offering of attractive discounts and the facility for home delivery and online payment gateways ate contributing to the growth of the market. The market players are adopting advanced technologies such as 3-D imaging systems to determine the way for optimal cuts and minimize the per-unit cost for poultry processing. The use of latest technologies and the development of efficient distribution channels is expected to propel the growth of the Poultry market till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based management consulting firm.

“Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia Poultry market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of Saudi Arabia Poultry market.

Browse Related Reports:

Global Organic Food Market By Product Type (Organic Meat, Poultry & Dairy; Organic Fruits & Vegetables; Organic Processed Food; Organic Bread & Bakery; Organic Beverages; Organic Processed Food and Others), By Distribution Channel Type (Hypermarket/Supermarket, Speciality Stores, Departmental Stores, Online and Others (Spices, Pulses, Cereals &Food Grains etc.), By Region, Competition, Forecast Opportunities, 2026

https://www.techsciresearch.com/report/organic-food-market/4401.html

Vietnam Frozen Food Market By Category, ((Ready-to-Eat, Ready-to-Cook & Others (Raw Meat, Raw Vegetables, Raw Fruit, etc.)), By Product Type (Frozen Meat, Poultry, & Seafood, Frozen Snacks, Frozen Fruits & Vegetables, Frozen Desserts, Frozen Cooked Ready Meals, & Others), By Distribution Channel (Departmental Stores, Specialty Stores, Supermarket/Hypermarket, Online & Others (Convenience Stores, Direct Sales, etc.)), By Region, Competition, Forecast Opportunities, 2026F

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Global Outpatient Hospital Services Market By Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures, Others) By Type (Emergency Department, Urgent Care Centers, Primary Care Clinics, Specialized Outpatient Clinics, Others) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

Saudi Arabia Seafood Market By Product (Fish, Shrimp, Crab, Lobster, Others) By Type (Raw, Frozen, Processed) By Application (Retail, Institution Sales and Food Service) By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Specialized Stores, Online, Others), Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[techscimarketresearch]

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

According to TechSci Research report, “Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026”, The Saudi Arabia Poultry market is expected to witness steady growth in the forecast period. The rapid urbanization of the people to live in better conditions and search for employment opportunities is contributing to the growth of the poultry market and enhancing the demand for processed and unprocessed chicken and eggs.

Support of the leading authorities for the development of the poultry market in form of relaxation in income tax, direct subsidies for select food items, interest-free loans, and duty-free imports of raw materials. The leading authorities are providing support to the local manufacturers and taking significant measures to reduce the mortality rate of the bird. An increase in the preference of the consumers for low-fat and high-protein-containing food items is fostering the growing demand of the market. The development of the trade channel and the technological advancements to keep the freshness of the food items and aid in increasing the shelf life of the edible animal food items is fostering the growth of the poultry market.

The increase in the demand for frozen and chilled food items is influencing the demand for poultry-based products in the region. The high demand for the consumption of poultry-based products and the unavailability of quality animal-based edible items in the country and the need to import the animal-based food items are creating lucrative opportunities for the growth of the poultry market. The Saudi government is making heavy investments for the infrastructural development of the country in order to develop the retail and hospitality sector in the country. Under the Saudi Vision 2030, the development of the tourism industry to attract more tourists to the country for religious and other purposes, the government is aiming to develop the poultry sector to meet the growing food requirements.

The COVID-19 outbreak across the world which has been declared as a pandemic by World Health Organization has affected several countries adversely. Leading authorities of Saudi Arabia imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. The coronavirus pandemic hit the economic status of the country which negatively impacted the growth of the industry. Disruption in the supply chain was observed which adversely affected the supply of raw materials around the country.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Saudi Arabia Poultry market is segmented into type, product type, nature, distribution channel, regional distribution, and company. Based on the type, the market can be divided into broiler, eggs, and others. The broiler segment is expected to witness growth in the next five years, 2022-2026. The rise in the demand for whole chicken and its parts and the increasing affordability of the consumers is fostering the growth of this segment. The Hajj pilgrimage attracts a lot of tourists in the country which is expected to fuel the demand and rapid development of the catering service market.  The rise in the development of the construction industry and the liability of the company to provide three meals a day is contributing to the growth of the poultry market as the normal diet in Saudi Arabia includes the portion of animal meat or products.

Almarai Saudi Arabia, Al-Watania Poultry Company, Al-Fakeih Poultry, Al-Berri United Food Co. Ltd, Alwadi Poultry Farms Ltd, Co., Arabian Agricultural Services Company, Arabian Farms Dev.Co.Ltd., Alsalamah Almotatawera Co, BRF S.A, Bayle S.A., Cargill Incorporated, Cherkizovo Group are the leading players operating in Saudi Arabia Poultry market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several Poultry manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

“Development of the online commerce channels to improve the reach of products and brand image, the market players are investing huge amounts. The offering of attractive discounts and the facility for home delivery and online payment gateways ate contributing to the growth of the market. The market players are adopting advanced technologies such as 3-D imaging systems to determine the way for optimal cuts and minimize the per-unit cost for poultry processing. The use of latest technologies and the development of efficient distribution channels is expected to propel the growth of the Poultry market till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based management consulting firm.

“Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia Poultry market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of Saudi Arabia Poultry market.

Browse Related Reports:

Global Organic Food Market By Product Type (Organic Meat, Poultry & Dairy; Organic Fruits & Vegetables; Organic Processed Food; Organic Bread & Bakery; Organic Beverages; Organic Processed Food and Others), By Distribution Channel Type (Hypermarket/Supermarket, Speciality Stores, Departmental Stores, Online and Others (Spices, Pulses, Cereals &Food Grains etc.), By Region, Competition, Forecast Opportunities, 2026

https://www.techsciresearch.com/report/organic-food-market/4401.html

Vietnam Frozen Food Market By Category, ((Ready-to-Eat, Ready-to-Cook & Others (Raw Meat, Raw Vegetables, Raw Fruit, etc.)), By Product Type (Frozen Meat, Poultry, & Seafood, Frozen Snacks, Frozen Fruits & Vegetables, Frozen Desserts, Frozen Cooked Ready Meals, & Others), By Distribution Channel (Departmental Stores, Specialty Stores, Supermarket/Hypermarket, Online & Others (Convenience Stores, Direct Sales, etc.)), By Region, Competition, Forecast Opportunities, 2026F

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Global Outpatient Hospital Services Market By Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures, Others) By Type (Emergency Department, Urgent Care Centers, Primary Care Clinics, Specialized Outpatient Clinics, Others) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

Saudi Arabia Seafood Market By Product (Fish, Shrimp, Crab, Lobster, Others) By Type (Raw, Frozen, Processed) By Application (Retail, Institution Sales and Food Service) By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Specialized Stores, Online, Others), Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[kennethresearch]

Global Asparaginase Market, June 2021 Report On Analysis 2021, Size, Top Players with Share, Total Revenues, Product Scope, Business Development and Opportunities till 2030

In a recently published report, Global Asparaginase Market report for till 2030. The report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to regain 25% by the end of 2021- Positive Growth in the economic demand and supply.

U S Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mention the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Global Asparaginase Market products.

Get Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

It is also anticipated to grow on account of the growing demand for chemicals from the end users, backed by the increasing consumption of chemicals across different industries and the rising need for advanced chemicals. In India, the production of major chemicals and petrochemicals during the period 2020-2021 was close to 12000 thousand MT. Additionally, between the period 2015-16 and 2019-20, the production of the chemicals and petrochemicals in the nation grew at a CAGR of close to 6%.

Global Asparaginase Market is valued approximately at USD XXX million in 2018 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2019-2026. Asparaginase is an enzyme which catalzes the hydrolysis of l-asparagine to l-aspartic acid and ammonia. Asparaginase products are isolated from different types of bacteria, namely Escherichia coli and Erwinia chrysanthemi. They inhibit protein synthesis in tumor cells by depriving them of the amino acid asparagine. These are used widely in Healthcare industry and Food manufacturing industry as a medication. It is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. As Asparaginase was approved for medical use in the United States in 1978. It is also on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. Asparaginase is used in the food manufacturing to reduce the formation of acrylamide. Acrylamide is a carcinogen in the starch containing food products such as biscuits and snacks. Thus, the rapidly growing healthcare and food manufacturing industry increase the demand for Asparaginase during the forecast period. As the Food and drinks market in Europe contributed to be the largest manufacturing sector in 2017 with a turnover of USD 1222 billion. The same sector invested USD 3.12 billion in research & development in 2017 which shows a positive sign in the market growth. Further, the rising investments of the market players for the research and development and production of Asparaginase according to the regulatory specification due to the rise in demand further fuels the market growth. However, the side effects of Asparaginase on human body such as mild bone marrow suppression, pancreatitis, anticoagulant factor resulting in stroke and bleeding hinders the market growth.

The regional analysis of global Asparaginase market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the dominant pharmaceutical industry in the region which is the major industry which uses Asparaginase enzyme. Further rising cases of Leukemia in the region propel the market growth. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as increasing population along with increasing disposable income coupled with growing food manufacturing industry would create lucrative growth prospects for the Asparaginase market across Asia-Pacific region.

Major market player included in this report are: Jazz Pharmaceuticals Plc Shire Plc Medac GmbH Kyowa Hakko Kirin Co., Ltd. Qianhong Bio-pharma Taj Pharmaceuticals Mingxing Pharma Exova SL Pharma Inc United Biotech Pvt. Ltd. Novus Biologicals The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: By Type: Escherichia Coli Erwinia Chrysanthemi Pegylated By Application: Healthcare Food Industry Others By Region: North America U.S. Canada Europe UK Germany Asia Pacific China India Japan Latin America Brazil Mexico Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017 Base year – 2018 Forecast period – 2019 to 2026

Target Audience of the Global Asparaginase Market in Market Study:

Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investor

Download Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : Sales@kennethresearch.com

Phone: +1 313 462 0609

[marketresearchtrendsblog]

Leukemia Therapeutics Market By Therapy Analysis, Trends – Global Forecast by 2020 - 2025

Uncontrolled growth of cells is caused due to mutation to genes in cancer. The uncontrolled grown cell again moves from one part of body to another through blood and lymph system. There are different types of cancer out of which Leukemia is one. Cancer which is formed in blood tissues is called as Leukemia. Leukemia occurs due to the uncontrolled growth of with blood cells in the bone marrow. White blood cells are the protectors of our body from different infections. Leukemia is the most common type of cancer that is caused among adult males because they are not diagnosed at proper time. The most familiar syndrome of Leukemia is weight loss, night sweats, fever, frequent infections and enlarged liver size. There are different types of Leukemia out of which are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia.

How Big is the Global Leukemia Therapeutics Market?

The Global Leukemia Therapeutic Market is expected to be around US$ 13 Billion by 2025 at a CAGR of 4% in the given forecast period.

The major driving factors of Global Leukemia Therapeutic Market are as follows:

Novel developments for drug discovery approaches Increase incidence number of target disease Increase aging population Not much competition in the market

The restraining factors of Global Leukemia Therapeutic Market are as follows:

Expensive treatment Adverse effect of the treatment

Read more information about Global Market with Impact of Covid-19

To get Sample Copy of Business Report through this link: https://www.sdki.jp/sample-request-105927

The Global Leukemia Therapeutic Market is segmented on the lines of its therapy, type and regional. Based on therapy segmentation it covers Chemotherapy, Biological Therapy, Radiation therapy, Targeted therapy, other. Based on type segmentation it covers Chronic leukemia, acute leukemia, others. The Global Leukemia Therapeutic Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

This report provides:

An overview of the global market for Global Leukemia Therapeutic Market and related technologies.

Analyses of global market trends, with data from 2016, estimates for 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2025.

Identifications of new market opportunities and targeted promotional plans for Global Leukemia Therapeutic Market.

Discussion of research and development, and the demand for new products and new applications.

Comprehensive company profiles of major players in the industry.

REPORT SCOPE:

The scope of the report includes a detailed study of global and regional markets on Global Leukemia Therapeutic Market with the reasons given for variations in the growth of the industry in certain regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc. Genzyme Corporation, AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.

The Global Leukemia Therapeutic Market has been segmented as below:

By Therapy Analysis:

Chemotherapy Biological Therapy Radiation therapy Targeted therapy Other

By Type Analysis:

Chronic leukemia Chronic lymphatic leukemia Chronic myeloid leukemia Acute leukemia Acute lymphatic leukemia Acute myeloid leukemia Others

By Regional Analysis:

North America Europe Asia-Pacific Rest of the World

Reasons to Buy this Report:

Obtain the most up to date information available on all Global Leukemia Therapeutic Market.

Identify growth segments and opportunities in the industry.

Facilitate decision making on the basis of strong historic and forecast of Global Leukemia Therapeutic Market data.

Assess your competitor’s refining portfolio and its evolution.

Original Source of this content: https://www.sdki.jp/reports/leukemia-therapeutics-market/105927

For more information, Please contact us now:

Shibuya Data Count

Email: sales@sdki.jp

Tel: + 81 3 45720790

[healtcare]

Global Haematology and Flow Cytometry Market

Global Haematology and Flow Cytometry Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.

Global Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays. Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years. To know about the Research Methodology :- Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period. This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.

[rdagade]

Global Haematology and Flow Cytometry Market

Global Haematology and Flow Cytometry Market

is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.

Global Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells.

Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives.

ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth.

The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays.

Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years.

To know about the Research Methodology :-

Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period.

This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-haematology-and-flow-cytometry-market/98749/

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

[newsbulletin]

Blood Cancer Drugs Market Competitive Strategies And Global Review 2017-2025

New York, NY 13 May 2021: The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.

The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.

Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.

Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample

The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.

On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.

Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.

To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing

The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.

Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.

Polaris Market Research has segmented the global blood cancer drugs market on the basis of type, drugs, treatment approaches and region:

Blood cancer drugs market Size and Forecast, 2017-2025 by Blood Cancer Type

Lymphoma

Leukemia

Myeloma

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

B-cell Lymphoma

T-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Mantle Cell Lymphoma

Burkitt Lymphoma

Central Nervous System Lymphoma

Precursor T-Lymphoblastic Lymphoma

Peripheral T-Lymphoma

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Acute Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Multiple Myeloma

Blood cancer drugs market Size and Forecast, 2017-2025 by Drugs

Rituaxan/Mabthera (Rituximab)

Gleevac/Glivec (Imatinib)

Revlimid (Lenalidomide)

Velcade (Bortezomib)

Tasigna (Nilotinib)

Pomalyst (Pomalidomide)

Vidaza (Azacitidine)

Kyprolis (Carfilzomib)

Adcetris (Brentuximab Vedotin)

Others

Blood cancer drugs market Size and Forecast, 2017-2025 by Treatment Approaches

Chemotherapeutic

mAbs/Targeted Therapies

Immunotherapeutic

Have Any Query or Specific Requirement? Request for customization: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-customization

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Contact Us:

Polaris Market Research

Phone: 1–646–568–9980

Email: sales@polarismarketresearch.com

Web: http://www.polarismarketresearch.com

[cool-akashy-maximize]

Global Leukemia Therapeutics Market : Industry Analysis and Forecast (2019-2027)

Global Leukemia Therapeutics Market was valued at US$ 11.32 Bn in 2019 and is expected to reach US$ 19.2 Bn by 2027, at a CAGR of 7.84 % during the forecast period.

The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region. Global Leukemia Therapeutics MarketGlobal Leukemia Therapeutics Market Dynamics:

Increased prevalence of cancer especially blood cancer across the globe is leading to increasing demand for effective treatments, which is the driving factor for market growth. Increase in expenditure on the development of novel treatment and developing health infrastructure is further driving the market growth. Additionally, the growth in survival rate and minimum side effects of novel treatment such as stem cell therapy, bone marrow transplant has open new avenues for market growth. Also, increased exposer to chemical mutation, changing dietary habits, and the living style of the population is further pushing the market growth.

The lack of early diagnosis and awareness among the public are leading challenges in the market for leukemia therapeutics. Furthermore, redefining the drug lifecycle roadmap is a major challenge for drug innovators. However, breakthrough therapy designations and accelerated approvals granted by regulatory bodies like the FDA would offer lucrative market opportunities for the drug innovators. Segment Analysis of the Global Leukemia Therapeutics Market:

Based on treatment type, chemotherapy led the segment in 2019. Because of its ability to kill cancerous cells or inhibiting their proliferation and maintain a normal level of lymphocytes of chemotherapy, is driving the market growth. Similarly, the increased survival rate of the patients treated with chemotherapy is again fueling its demand.

On the basis of the type of leukemia, acute lymphocytic leukemia is dominating the segment and has accounted for maximum market share. Owing to the rising condition of cancerous cells, acute leukemia is driving the segment growth. Increasing smoking habits, exposure to chemicals, radiation, and cases with other blood-related disorders are again driving the segment growth. Regional Insights of the Global Leukemia Therapeutics Market:

In terms of region, North America followed by Europe dominates the global leukemia therapeutics market owing to the growing incidence of cancer and increasing aging population. The APAC is expected to show a high growth rate because of the increasing incidence of cancer. China and India are expected to be the fastest-growing leukemia markets in the Asia Pacific region. Some of the key driving forces for the leukemia therapeutic market in emerging economies are increasing R&D investment, a large pool of patients, and growing government funding.

Key developments in leukemia therapeutics market: In February 2018, Sanofi announced to discard the mid-stage exertion on ALL therapy for the anti-CD38 antibody isatuximab. Also, Erytech Pharma broadened the scope of eryaspase (GRASPA) growth for solid tumors further clinical studies in triple-negative breast cancer.

The objective of the report is to present a comprehensive assessment of the market and contain thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Leukemia Therapeutics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. Scope of the Global Leukemia Therapeutics Market Report:

Global Leukemia Therapeutics Market, by Type of Leukemia

• Chronic Myeloid Leukemia • Chronic Lymphocytic Leukemia • Acute Lymphocytic Leukemia • Acute Myeloid Leukemia

Global Leukemia Therapeutics Market, by Treatment Type

• Targeted Drugs & Immunotherapy • Chemotherapy

Global Leukemia Therapeutics Market, by Molecule Type

• Small Molecules • Biologics

Global Leukemia Therapeutics Market, by Mode of Administration

• Oral Mode • Injectable Mode

Global Leukemia Therapeutics Market, by Gender

• Males • Females

Global Leukemia Therapeutics Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America Key Players Operating in the Global Leukemia Therapeutics Market:

• Novartis AG • AbbVie • Bristol-Myers Squibb • Hoffmann-La Roche • Sanofi • Pfizer • Amgen • Gilead Sciences • Takeda • Celgene • AbARIAD Pharmaceuticals, Inc. • F. Hoffmann-La Roche Ltd. • Genzyme Corporation • GlaxoSmithKline plc. • Teva Pharmaceuticals • Allergan, • AstraZeneca, • F. Hoffmann-La Roche Ltd, • Pfizer Inc., • Merck KGaA, Merck & Co., Inc.,

For More Information Visit @: This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.